Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lymphatic Diseases 2Immunoproliferative Disorders 2Hematologic Diseases 2

Interventions

Cyclophosphamide 14fludarabine 12fludarabine phosphate 8Melphalan 8Brentuximab Vedotin 8Whole-Body Irradiation 7Mycophenolic Acid 7Busulfan 7Rituximab 6Tacrolimus 5Lenalidomide 4Etoposide 4isatuximab 3Sirolimus 3Mesna 3Granulocyte Colony-Stimulating Factor 3Dexamethasone 3pembrolizumab 2nilotinib 2dacetuzumab 2Vincristine 2Thiotepa 2Sugars 2Stem Cell Transplantation 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Ondansetron 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Diseases × dacetuzumab × Clear all
NCT00529503 2015-02-25

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Seagen Inc.

Phase 2 Terminated
151 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

NCT00435916 2015-01-07

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Completed
46 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡